Evidence map›Paper›PMID 32011186›Full record

SynthesisExpert opinion on pharmacotherapy2020

Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.

Karolina Kozak, Tony P George

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Expert opinion on pharmacotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Smoking in Substance Use Disorder Patients: Prevalence, Comorbidities, Impulsivity, and Patterns of Readiness to Change.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Article
  4. Article
  5. Training in Substance use Disorders, Part 1: Overview of Clinical Practice Recommendations.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Karolina KozakInstitute of Medical Science (IMS), Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Tony P GeorgeInstitute of Medical Science (IMS), Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Centre for Addiction and Mental Health · CAUniversity of Toronto · CA

Funding

Effects of rTMS on Cannabis Use and Cognitive Outcomes in SchizophreniaR21DA043949 · NIDA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI GEORGE, TONY P · 2017 to 2018
$286k
NIDA NIH HHS R21 DA043949
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BenzazepinesBupropionHumansNicotinic AgonistsQuinoxalinesSchizophreniaSmokingSmoking CessationTobacco Use Cessation DevicesVareniclineBenzazepinesBupropionNicotinic AgonistsQuinoxalinesVareniclinebupropionnicotine replacement therapyrisk ratiosSchizophreniasmoking cessationvarenicline

Identifiers

PMID32011186
PMCPMC7183430
OpenAlexW3005302028

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.